Treatment of heart failure with preserved systolic function

Archives of Cardiovascular Diseases

Volumn 101, Issue 5, 2008, Pages 361-372

  de Groote, P ^a   Herpin, D ^b   Dievart F ^c   Hanon, O ^d   Trochu, J N ^e   Artigou, J Y ^f   Galinier, M ^g   Habib, G ^h   Juilliere Y ⁱ   Neuder, Y ^j   Roudaut, R ^k   Komajda, M ^l  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE POITIERS   (France)

^c Clinique Villette   (France)

^d Paris Descartes University   (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f AVICENNE HOSPITAL   (France)

^g CHU RANGUEIL   (France)

^h TIMONE HOSPITAL   (France)

ⁱ CHU NANCY BRABOIS   (France)

^j GRENOBLE UNIVERSITY HOSPITAL   (France)

^k HAUT LÉVÊQUE HOSPITAL   (France)

^l PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NEBIVOLOL; PERINDOPRIL; PLACEBO;

ANGIOPLASTY; ARTIFICIAL HEART PACEMAKER; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; EDUCATION PROGRAM; EXERCISE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY ARTERY STENOSIS; LIFESTYLE; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT EDUCATION; PROGNOSIS; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SIDE EFFECT; SMOKING CESSATION; SODIUM RESTRICTION; SURVIVAL RATE; SYSTOLE; TREATMENT OUTCOME;

EID: 49749143333     PISSN: 18752136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acvd.2008.04.008     Document Type: Review

References (82)

1. Juilliere Y, Trochu JN, de Groote P, et al. Heart failure with pre-served systolic function: a diagnostic algorithm for a pragmatic definition. Arch Mal Coeur Vaiss 2006;99:279-86.
2. Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28: 2539-50.
3. Kitzman DW, Higginbotham MB, Cobb FR, Sheikh KH, Sullivan MJ. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starting mechanism. J Am Coll Cardiol 1991;17:1065-72.
4. Mosterd A, D'Agostino RB, Silbershatz H, et al. Trends in the prevalence of hypertension, anti hypertensive therapy, and left ventricutar hypertrophy from 1950 to 1989. N Engl J Med 1999;340:1221-7.
5. Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. Ann Intern Med 1969;71: 89-105.
6. Cuspidi C, Lonati L, Sampieri L, et al. Impact of blood pressure control on prevalence of left ventricular hypertrophy in treated hypertensive patients. Cardiology 2000;93:149-54.
7. Schmieder RE, Messerli FH, Garavaglia GE, Nunez BD. Dietary salt intake. A determinant of cardiac involvement in essential hypertension. Circulation 1988;78:951-6.
8. Manotio TA, Levy D, Garrison RJ, Castelli WP, Kannel WB. Relation of alcohol intake to left ventricular mass: The Framingham Study. J Am Coll Cardiol 1991; 17:717-21.
9. Garavaglia GE, Messerli FH, Schmieder RE, Nunez BD, Oren S. Sex differences in cardiac adaptation to essential hypertension. Eur Heart J 1989;10:1110-4.
10. Kupari M, Koskinen P, Virolainen J. Correlates of left ventricular mass in a population sample aged 36 to 37 years. Focus on lifestyle and salt intake. Circulation 1994;89: 1041-50.
11. Ravogli A, Trazzi S, Villani A, et al. Early 24-hour blood pressure elevation in normotensive subjects with parental hypertension. Hypertension 1990;16:491-7.
12. Koren MJ, Mensah GA, Blake J, Laragh JH, Devereux RB. Comparison of left ventricular mass and geometry in black and white patients with essential hypertension. Am J Hypertens 1993;6:815-23.
13. Esposito G, Rapacciuolo A, Naga Prasad SV, et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 2002;105:85-92.
14. Haider AW, Larson MG, Franklin SS, Levy D. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 2003;138:10-6.
15. Dahlof B. Factors involved in the pathogenesis of hypertensive cardiovascular hypertrophy A review. Drugs 1988;35(Suppl 5):6-26.
16. Kaneko K, Susic D, Nunez E, Frohlich ED. ACE inhibition reduces left ventricular mass independent of pressure without affecting coronary flow and flow reserve in spontaneously hypertensive rats. Am J Med Sci 1997;314:21-7.
17. Nagano M, Higaki J, Mikami H, et al. Converting enzyme inhibitors regressed cardiac hypertrophy and reduced tissue angiotensin II in spontaneously hypertensive rats. J Hypertens 1991;9:595-9.
18. Sabri A, Samuel JL, Marotte F, Poitevin P, Rappaport L, Levy BI. Microvasculature in angiotensin II-dependent cardiac hypertrophy in the rat. Hypertension 1998;32:371-5.
19. Weber KT, Sun Y, Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 1994;23:869-77.
20. Sen S, Tarazi RC, Bumpus FM. Cardiac hypertrophy and antihypertensive therapy. Cardiovasc Res 1977;11:427-33.
21. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ, The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six anti hypertensive agents. Circulation 1997;95:2007-14.
22. Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995;91:698-706.
23. Gosse P, Dubourg O, Gueret P. Regression of left ventricular hypertrophy with echocardiography: some lessons from the LIVE study. J Hypertens 2003;21:217-21.
24. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-anatysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003;115:41-6.
25. Devereux RB, Palmieri V, Sharpe N, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalaprit study evaluating regression of ventricular enlargement (PRESERVE) trial. Circulation 2001;104:1248-54.
26. Gosse P, Sheridan DJ, Zannad F, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalaprit 20 mg: the LIVE study. J Hypertens 2000;18:1465-75.
27. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
28. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995;13:1091-5.
29. Yurenev AP, Dyakonova HG, Novikov ID, et al. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy. Multicenter trial. Am J Hypertens 1992;5:182S-9S.
30. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998;97:48-54.
31. Cipriano C, Gosse P, Bemurat L, et al. Prognostic value of left ventricutar mass and its evolution during treatment in the Bordeaux cohort of hypertensive patients. Am J Hypertens 2001;14:524-9.
32. Devereux RB, Dahlof B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004;110:1456-62.
33. Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004;292:2350-6.
34. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-25.
35. Pickering TG, Herman L, Devereux RB, et al. Recurrent pulmonary oedema in hypertension due to bilateral renal artery stenosis: treatment by angioplasty or surgical revascularisation. Lancet 1988;2:551-2.
36. Bloch MJ, Trost DW, Pickering TG, Sos TA, August P, Prevention of recurrent pulmonary edema in patients with bilateral renovascular disease through renal artery stent placement. Am J Hypertens 1999;12:1-7.
37. Nayler WG, Pooie-Wilson PA, Williams A. Hypoxia and calcium. J Mol Cell Cardiol 1979;11:683-706.
38. Mahmarian JJ, Pratt CM. Silent myocardial ischemia in patients with coronary artery disease. Possible links with diastolic left ventricutar dysfunction. Circulation 1990;81:III33-40.
39. Galderisi M, Cicala S, Caso P, et al. Coronary flow reserve and myocardial diastolic dysfunction in arterial hypertension. Am J Cardiol 2002;90:860-4.
40. Clark J, Garfein OB, Dwyer Jr EM. Acute pulmonary edema due to ischemic heart disease without accompanying myocardial infarction. Natural history and clinical profile. Am J Med 1983;75:332-6.
41. Labovitz AJ, Lewen MK, Kern M, Vandormael M, Deligonal U, Kennedy HL. Evaluation of left ventricular systolic and diastolic dysfunction during transient myocardial ischemia produced by angioplasty. J Am Coll Cardiol 1987;10:748-55.
42. Bogaty P, Mure P, Dumesnil JG. New insights into diastolic dysfunction as the cause of acute left-sided heart failure associated with systemic hypertension and/or coronary artery disease. Am J Cardiol 2002;89:341-5.
43. Arques S, Ambrosi P, Gelisse R, Roux E, Lambert M, Habib G. Prevalence of angiographic coronary artery disease in patients hospitalized for acute diastolic heart failure without clinical and electrocardiographic evidence of myocardial ischemia on admission. Am J Cardiol 2004;94:133-5.
44. Judge KW, Pawitan Y, Caldwell J, Gersh BJ, Kennedy JW. Congestive heart failure symptoms in patients with preserved left ventricutar systolic function: analysis of the CASS registry. J Am Coll Cardiol 1991;18:377-82.
45. Kramer K, Kirkman P, Kitzman D, Little WC. Flash pulmonary edema: association with hypertension and reoccurrence despite coronary revascularization. Am Heart J 2000;140:451-5.
46. Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35.
47. Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006;355:2395-407.
48. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the aduLt: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001;38:2101-13.
49. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-235.
50. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40.
51. McMurray J, Swedberg K. Treatment of chronic heart failure: a comparison between the major guidelines. Eur Heart J 2006;27:1773-7.
52. Berger RD, Wolff MR, Anderson JH, Kass DA. Role of atrial contraction in diastolic pressure elevation induced by rapid pacing of hypertrophied canine ventricle. Circ Res 1995;77:163-73.
53. Friedrich SP, Lorell BH, Rousseau MF, et al. Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis. Circulation 1994;90:2761-71.
54. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998;98: 2282-9.
55. Philbin EF, Rocco Jr TA, Lindenmuth NW, Ulrich K, Jenkins PL. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med 2000;109:605-13.
56. Masoudi FA, Havranek EP, Smith G, et al. Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2003;41:217-23.
57. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006;47:76-84.
58. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006;296:2217-26.
59. Berry C, Hogg K, Norrie J, Stevenson K, Brett M, McMurray J. Heart failure with preserved left ventricular systolic function: a hospital cohort study. Heart 2005;91:907-13.
60. Grigorian Shamagian L, Gonzalez-Juanatey JR, Roman AV, Acuna JM, Lamela AV. The death rate among hospitalized heart failure patients with normal and depressed left ventricular ejection fraction in the year following discharge: evolution over a 10-year period. Eur Heart J 2005;26:2251-8.
61. Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med 2002;137:631-9.
62. Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003;24:464-74.
63. Lenzen MJ, Scholte op Reimer WJ, Boersma E, et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 2004;25:1214-20.
64. Bursi F, Weston SA, Redfield MM, et al. Systolic and diastolic heart failure in the community. JAMA 2006;296:2209-16.
65. Ahmed A, Roseman JM, Duxbury AS, Allman RM, DeLong JF. Correlates and outcomes of preserved left ventricular systolic function among older adults hospitalized with heart failure. Am Heart J 2002;144:365-72.
66. Dobre D, van Veldhuisen DJ, DeJongste MJ, et al. Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival. Eur J Heart Fail 2007;9:280-6.
67. Aronow WS, Ahn C, Kronzon I. Effect of propranolot versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol 1997;80: 207-9.
68. Borghi C, Ambrosioni E. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Am Heart J 2007;153(445):e7-14.
69. Bertrand ME, Remme WJ, Fox KM, Ferrari R, Simoons ML. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function. Int J Cardiol 2007;121:57-61.
70. Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 2006;114:397-403.
71. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-81.
72. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivotol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25.
73. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27: 2338-45.
74. Carson P, Massie BM, McKelvie R, et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail 2005;11: 576-85.
75. Tresch DD. The clinical diagnosis of heart failure in older patients. J Am Geriatr Soc 1997;45:1128-33.
76. The SAGE Study GroupGambassi G, Forman DE, Lapane KL, et al. Management of heart failure among very old persons living in long-term care: has the voice of trials spread? Am Heart J 2000;139:85-93.
77. Komajda M, Hanon O, Hochadet M, et al. Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I. Eur Heart J 2006;28:1310-8.
78. Komajda M, Forette F, Aupetit JF, et al. Recommendations for the diagnosis and management of cardic failure in the elderly subject. Arch Mal Coeur Vaiss 2004;97:803-22.
79. Galbreath AD, Krasuski RA, Smith B, et al. Long-term health-care and cost outcomes of disease management in a large, randomized, community-based population with heart failure. Circulation 2004;110:3518-26.
80. Gary RA, Sueta CA, Dougherty M, et al. Home-based exercise improves functional performance and quality of life in women with diastolic heart failure. Heart Lung 2004;33:210-8.
81. Dubourg O, Gueret P, Beauchet A, Nisse-Durgeat S, Ducardonnet A. Focale: Study of systolic and diastolic heart failure in a French elderly population. Int J Cardiol 2007;124:188-92.
82. Smith GL, Masoudi FA, Vaccarino V, Radford MJ, Krumholz HM. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional dectine. J Am Coll Cardiol 2003;41:1510-8.